Wasatch Advisors LP Buys 346,720 Shares of Repligen Corporation $RGEN

Wasatch Advisors LP grew its position in shares of Repligen Corporation (NASDAQ:RGEN) by 27.9% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,590,251 shares of the biotechnology company’s stock after purchasing an additional 346,720 shares during the period. Repligen makes up approximately 1.4% of Wasatch Advisors LP’s investment portfolio, making the stock its 19th biggest position. Wasatch Advisors LP’s holdings in Repligen were worth $216,974,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in RGEN. Handelsbanken Fonder AB boosted its stake in Repligen by 11.8% during the second quarter. Handelsbanken Fonder AB now owns 22,070 shares of the biotechnology company’s stock valued at $3,011,000 after buying an additional 2,332 shares during the last quarter. Everhart Financial Group Inc. purchased a new position in Repligen during the 2nd quarter valued at approximately $303,000. Assenagon Asset Management S.A. bought a new stake in Repligen in the 2nd quarter worth approximately $9,687,000. Balefire LLC bought a new stake in Repligen in the 2nd quarter worth approximately $275,000. Finally, GAMMA Investing LLC increased its position in Repligen by 28.7% in the second quarter. GAMMA Investing LLC now owns 1,944 shares of the biotechnology company’s stock worth $265,000 after purchasing an additional 433 shares during the last quarter. 97.64% of the stock is owned by institutional investors.

Repligen Price Performance

RGEN stock opened at $164.77 on Wednesday. The stock has a market cap of $9.30 billion, a PE ratio of 225.71, a P/E/G ratio of 2.97 and a beta of 1.03. Repligen Corporation has a 12 month low of $100.99 and a 12 month high of $175.77. The company has a 50-day moving average price of $140.11 and a 200 day moving average price of $131.05. The company has a current ratio of 9.05, a quick ratio of 7.64 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share for the quarter, topping analysts’ consensus estimates of $0.45 by $0.09. The company had revenue of $204.13 million for the quarter, compared to analyst estimates of $201.59 million. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The firm’s revenue for the quarter was up 11.9% on a year-over-year basis. During the same period in the prior year, the company posted $0.26 EPS. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. Equities research analysts anticipate that Repligen Corporation will post 2.06 earnings per share for the current year.

Insider Activity at Repligen

In other news, CFO Jason K. Garland sold 733 shares of the stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $145.00, for a total value of $106,285.00. Following the sale, the chief financial officer directly owned 19,359 shares in the company, valued at approximately $2,807,055. This represents a 3.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.60% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the stock. Canaccord Genuity Group decreased their price target on shares of Repligen from $165.00 to $145.00 and set a “hold” rating on the stock in a research note on Monday, April 20th. Roth Capital assumed coverage on Repligen in a research report on Friday, April 17th. They issued a “buy” rating and a $160.00 price target for the company. Wells Fargo & Company upped their price objective on Repligen from $180.00 to $185.00 and gave the company an “overweight” rating in a research report on Thursday, July 30th. HSBC lowered their price objective on Repligen from $170.00 to $150.00 and set a “buy” rating for the company in a research note on Wednesday, June 3rd. Finally, JPMorgan Chase & Co. lifted their target price on Repligen from $165.00 to $175.00 and gave the stock an “overweight” rating in a report on Wednesday, July 29th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Repligen currently has an average rating of “Moderate Buy” and an average target price of $166.43.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.